<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890028</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2020-28</org_study_id>
    <nct_id>NCT04890028</nct_id>
  </id_info>
  <brief_title>Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases</brief_title>
  <acronym>DOPACER</acronym>
  <official_title>Detection and Metabolic Characterization in DOPA PET/CT of no Treated Brain Metastases of Lung Cancer, Breast Cancer and Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 20 to 30% of patients treated for cancer will have brain metastases. These brain&#xD;
      metastases are found more frequently in patients with lung cancer, breast cancer or melanoma.&#xD;
      The prognosis of these patients is unfavorable but prolonged survival can be obtained with&#xD;
      the local and systemic treatments currently available.&#xD;
&#xD;
      Brain MRI is the gold standard for evaluating brain metastases but has limitations in&#xD;
      therapeutic evaluation, partially offset by PET imaging of amino acid metabolism.&#xD;
&#xD;
      Our work aims to compare the performance of PET-DOPA with standard MRI for the detection of&#xD;
      brain metastases (≥ 5mm) in lung cancer, breast cancer and melanoma; and to characterize&#xD;
      these lesions using dynamic acquisitions obtained with a digital PET camera with high spatial&#xD;
      resolution. Having better knowledge of the metabolic characteristics of newly discovered&#xD;
      brain metastases, the objective of subsequent studies will be to better assess the per- or&#xD;
      post-therapeutic efficacy of radiotherapy and the various systemic therapies available&#xD;
      (chemotherapy, targeted therapy, immunotherapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the sensitivity of 18F DOPA PET-CT for the detection of no treated brain metastases (breast cancer, lung cancer, melanoma), newly diagnosed by MRI and measuring at least 5 mm in diameter.</measure>
    <time_frame>Within 8 months of PET-CT</time_frame>
    <description>The sensitivity of PET-DOPA to detect brain metastases greater than 5 mm is determined by the number of metastases detected with PET-DOPA compared to the number of metastases greater than 5 mm detected by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the sensitivity of 18F DOPA PET-CT according to the site of the primary tumor (lung cancer, breast cancer, melanoma) and its characteristics</measure>
    <time_frame>Within 8 months of PET-CT</time_frame>
    <description>The sensitivity per site will be calculated for 8 primary tumor categories: 3 for lung cancer (EGFR mutation or ALK rearrangement; PDL1 +; others), 2 for melanoma (BRAF V600 mutation; others), 3 for breast cancer (triple negative; Her2 + RH-; others)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Brain Metastases</condition>
  <condition>MRI</condition>
  <arm_group>
    <arm_group_label>F-DOPA PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 18 F-DOPA Radiation: F-DOPA PET CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>F-DOPA PET/CT</intervention_name>
    <description>All subjects will be imaged&#xD;
1 time injection of 2 MBq/kg of 18F-DOPA</description>
    <arm_group_label>F-DOPA PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primitive cancer (brest cancer, lung cancer, melanoma) proven histologically&#xD;
&#xD;
          -  Presence of brain metastasis visualized on MRI, of which at least one measures 5 mm&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patient has valid health insurance&#xD;
&#xD;
          -  Written informed consent obtained from the patient prior to performing any&#xD;
             protocol-related procedures, including screening evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of irradiation cerebral&#xD;
&#xD;
          -  History of brain surgery for brain metastasis or glial tumor&#xD;
&#xD;
          -  Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6&#xD;
             weeks preceding the realization of DOPA PET/CT,&#xD;
&#xD;
          -  New anti-tumor treatment started between the discovery of brain metastases and the&#xD;
             performance of DOPA PET/CT&#xD;
&#xD;
          -  Other concomitant cancer, or history of cancer in the 5 years preceding the&#xD;
             performance of DOPA PET/CT&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Persons deprived of their liberty, under a measure of safeguard of justice, under&#xD;
             guardianship or placed under the authority of a guardian.&#xD;
&#xD;
        Disorder precluding understanding of trial information or informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Morel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver MOREL, MD</last_name>
    <phone>241352700</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.morel@ico.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pacôme FOSSE, MD</last_name>
      <email>pafosse@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier MOREL, MD</last_name>
      <email>olivier.morel@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>DOPA PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

